Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022)

Enliven Therapeutics has reported Operating Leases over the past 2 years, most recently at $2.0 million for Q1 2022.

  • Quarterly results put Operating Leases at $2.0 million for Q1 2022, up 233.39% from a year ago — trailing twelve months through Mar 2022 was $2.0 million (up 233.39% YoY), and the annual figure for FY2021 was $406000.0, changed.
  • Operating Leases reached $2.0 million in Q1 2022 per ELVN's latest filing, up from $406000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $2.0 million in Q1 2022 and bottomed at $406000.0 in Q4 2021.